The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the ...
Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...
A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy - a cell-based cancer treatment that exploded on the scene in 2017 as a ...
The US Food and Drug Administration has launched an investigation into certain treatments for cancer and whether these therapies themselves may be associated with the risk of developing secondary ...
PHILADELPHIA – The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results